DelveInsight's Interleukin-17 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes ...

The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for deucravacitinib for the treatment of adults with active psoriatic arthritis (PsA).

Icotrokinra is a first-in-class targeted oral peptide that blocks interleukin (IL) 23 and its receptor, which plays a key role in the inflammatory response in plaque psoriasis.

Inference-based guidance supports using systemic psoriasis treatments in cancer patients on immune checkpoint inhibitors ...

Bristol Myers Squibb said the U.S. Food and Drug Administration has accepted its application seeking expanded approval of its plaque psoriasis drug Sotyktu for the treatment of adults with active ...

This was duly noted by Dr. Karen. Arriving at her salon, situated in her house in leafy Stoke Newington—two very sweet pugs ...

Self-care methods for psoriatic arthritis (PsA) include staying active with gentle exercises, getting enough sleep, and ...

Many people with psoriatic arthritis will experience symptoms in their feet. This can lead to swollen toes, pitted nails, ...

Dealing with the itchy, scaly patches that come with psoriasis is difficult enough. But having psoriasis puts you at risk of ...

The symptoms of this inflammatory disease can seem disconnected, which is why it’s important to know what to look for.

Discover a study showing low and stable cancer risk in patients with PsO, PsA, and axSpA treated long-term with ixekizumab.